Advertisement

Efficacy and Safety of Adalimumab and Infliximab for Noninfectious Uveitis

  • Felicia Tai
    Affiliations
    Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
    Search for articles by this author
  • Parsa Mehraban Far
    Affiliations
    Department of Ophthalmology, Kingston Health Sciences Center, Queen’s University, Kingston, Canada
    Search for articles by this author
  • Petros Pechlivanoglou
    Affiliations
    Toronto Health Economics and Technology Assessment (THETA) Collaborative, University Health Network, Toronto, Canada

    Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, University of Toronto, Toronto, Canada
    Search for articles by this author
  • Lauren C. Ramsay
    Affiliations
    Toronto Health Economics and Technology Assessment (THETA) Collaborative, University Health Network, Toronto, Canada

    Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
    Search for articles by this author
  • Jorge R. Georgakopoulos
    Affiliations
    Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Canada
    Search for articles by this author
  • Beate Sander
    Affiliations
    Toronto Health Economics and Technology Assessment (THETA) Collaborative, University Health Network, Toronto, Canada

    Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada

    Public Health Ontario, Toronto, Canada

    ICES, Toronto, Canada
    Search for articles by this author
  • Larissa A. Derzko-Dzulynsky
    Affiliations
    Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada

    Department of Ophthalmology, St. Joseph’s Health Centre, Unity Health Toronto, Toronto, Canada

    Department of Ophthalmology, St. Michael’s Hospital, Unity Health Toronto, Toronto, Canada
    Search for articles by this author
  • Tina Felfeli
    Correspondence
    Correspondence: Tina Felfeli, MD, Department of Ophthalmology and Vision Sciences, University of Toronto, 340 College Street, Suite 400, Toronto, ON M5T 3A9, Canada.
    Affiliations
    Toronto Health Economics and Technology Assessment (THETA) Collaborative, University Health Network, Toronto, Canada

    Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada

    Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada
    Search for articles by this author
Published:October 08, 2021DOI:https://doi.org/10.1016/j.ophtha.2021.09.025
      Noninfectious uveitis (NIU) is an immune-mediated response commonly associated with systemic diseases (e.g., Behçet’s disease) and nonsystemic inflammatory conditions (e.g., birdshot choroidopathy), or it may be idiopathic. Although corticosteroids are a mainstay of NIU treatment, steroid-sparing therapies such as anti–tumor necrosis factor α biologics and systemic immunomodulators allow for steroid tapering and mitigation of long-term side effects.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Atienza-Mateo B.
        • Martín-Varillas J.L.
        • Calvo-Río V.
        • et al.
        Comparative study of infliximab versus adalimumab in refractory uveitis due to Behçet’s disease: national multicenter study of 177 cases.
        Arthritis Rheumatol. 2019; 71: 2081-2089
        • Cecchin V.
        • Zannin M.E.
        • Ferrari D.
        • et al.
        Longterm safety and efficacy of adalimumab and infliximab for uveitis associated with juvenile idiopathic arthritis.
        J Rheumatol. 2018; 45: 1167-1172
        • Moher D.
        • Liberati A.
        • Tetzlaff J.
        • Altman D.G.
        Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement.
        BMJ. 2009; 339: b2535
        • Bressler N.M.
        • Bressler S.B.
        • Childs A.L.
        • et al.
        Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13.
        Ophthalmology. 2004; 111: 1993-2006
        • Maccora I.
        • Fusco E.
        • Marrani E.
        • et al.
        Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis.
        Rheumatology (Oxford). 2021; 60: 568-587
        • Jung Y.S.
        • Han M.
        • Park S.
        • Cheon J.H.
        Comparison of long-term outcomes of infliximab versus adalimumab in 1,488 biologic-naive Korean patients with Crohn’s disease.
        Gut Liver. 2021; 15: 92-99
        • van Dartel S.A.
        • Fransen J.
        • Kievit W.
        • et al.
        Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
        Ann Rheum Dis. 2013; 72: 895-900